Literature DB >> 17178109

Curcumin enhances cystic fibrosis transmembrane regulator expression by down-regulating calreticulin.

Kazutsune Harada1, Tsukasa Okiyoneda, Yasuaki Hashimoto, Kimiko Oyokawa, Kimitoshi Nakamura, Mary Ann Suico, Tsuyoshi Shuto, Hirofumi Kai.   

Abstract

Curcumin has been reported to correct cystic fibrosis caused by the DeltaF508 mutation of the cystic fibrosis transmembrane regulator (CFTR) but its mechanistic action remains unclear. We have recently demonstrated that the ER chaperone calreticulin (CRT) negatively regulates the CFTR cell surface expression and activity. Thus, we aimed at determining whether CRT mediates the effect of curcumin on CFTR. We show here that the treatment with curcumin of Chinese hamster ovary cells suppressed CRT expression and increased wild-type CFTR but did not affect DeltaF508 CFTR expression. However, we determined that although curcumin did not augment DeltaF508 CFTR expression, it enhanced the functional competence of DeltaF508 CFTR induced by 26 degrees C incubation. Knock down of CRT by siRNA at low-temperature had a similar effect. Our findings suggest that the positive effect of curcumin on CFTR expression is mediated through the down-regulation of CRT, a negative regulator of CFTR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178109     DOI: 10.1016/j.bbrc.2006.12.036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Calreticulin chaperones regulate functional expression of vomeronasal type 2 pheromone receptors.

Authors:  Sandeepa Dey; Hiroaki Matsunami
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

2.  Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression in cystic fibrosis airways: role in oxidant-mediated cell death.

Authors:  Shama Ahmad; Aftab Ahmad; Elena S Dremina; Victor S Sharov; Xiaoling Guo; Tara N Jones; Joan E Loader; Jason R Tatreau; Anne-Laure Perraud; Christian Schöneich; Scott H Randell; Carl W White
Journal:  Am J Respir Crit Care Med       Date:  2009-02-06       Impact factor: 21.405

3.  Transit defect of potassium-chloride Co-transporter 3 is a major pathogenic mechanism in hereditary motor and sensory neuropathy with agenesis of the corpus callosum.

Authors:  Adèle Salin-Cantegrel; Jean-Baptiste Rivière; Masoud Shekarabi; Sarah Rasheed; Sandra Dacal; Janet Laganière; Rébecca Gaudet; Daniel Rochefort; Gaëtan Lesca; Claudia Gaspar; Patrick A Dion; Jean-Yves Lapointe; Guy A Rouleau
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

4.  Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator.

Authors:  Xiu-Bao Chang; April Mengos; Yue-Xian Hou; Liying Cui; Timothy J Jensen; Andrei Aleksandrov; John R Riordan; Martina Gentzsch
Journal:  J Cell Sci       Date:  2008-08-05       Impact factor: 5.285

Review 5.  Potential for therapeutic manipulation of the UPR in disease.

Authors:  Sang Won Park; Umut Ozcan
Journal:  Semin Immunopathol       Date:  2013-04-10       Impact factor: 9.623

6.  Molecular Chaperones as Targets to Circumvent the CFTR Defect in Cystic Fibrosis.

Authors:  Rebecca A Chanoux; Ronald C Rubenstein
Journal:  Front Pharmacol       Date:  2012-07-17       Impact factor: 5.810

Review 7.  Calreticulin: roles in cell-surface protein expression.

Authors:  Yue Jiang; Sandeepa Dey; Hiroaki Matsunami
Journal:  Membranes (Basel)       Date:  2014-09-16

8.  CFTR-regulated MAPK/NF-κB signaling in pulmonary inflammation in thermal inhalation injury.

Authors:  Zhi Wei Dong; Jing Chen; Ye Chun Ruan; Tao Zhou; Yu Chen; YaJie Chen; Lai Ling Tsang; Hsiao Chang Chan; Yi Zhi Peng
Journal:  Sci Rep       Date:  2015-10-30       Impact factor: 4.379

9.  The effects of nano-curcumin as a nutritional strategy on clinical and inflammatory factors in children with cystic fibrosis: the study protocol for a randomized controlled trial.

Authors:  Saeedeh Talebi; Mahammad Safarian; Mahmood Reza Jaafari; Seyed Javad Sayedi; Zahra Abbasi; Golnaz Ranjbar; Hamid Reza Kianifar
Journal:  Trials       Date:  2021-04-20       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.